Pharma leaders are increasingly allocating budget toward real-time clinical alerts that integrate with and improve patient care. By investing in algorithms that auto-detect diseases as common as heart failure and as rare as pulmonary arterial hypertension, manufacturers can help accelerate time to diagnosis and treatment, streamline monitoring and identify new patients while starting them on the right therapies faster.
In this content, you’ll learn:
- How alerting can help develop underdiagnosed and misdiagnosed markets, such as rare diseases
- AI’s impact across speed-to-therapy and next-best-actions
- Opportunities for alerts to improve patient compliance and journeys
- What to look for in AI-powered alerting solution
